Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

被引：9
|
作者：
Vij, Ravi [1 ]
Martin, Thomas G., III [2 ]
Nathwani, Nitya [3 ]
Fiala, Mark A. [1 ]
Gao, Feng [1 ]
Deol, Abhinav [4 ]
Buadi, Francis K. [5 ]
Kaufman, Jonathan L. [6 ]
Hofmeister, Craig C. [6 ,7 ]
Gregory, Tara K.
Berdeja, Jesus G.
Chari, Ajai
Rosko, Ashley E. [8 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
[4] Wayne State Univ, Detroit, MI USA
[5] Mayo Clin, Rochester, MN USA
[6] Emory Univ, Sch Med, Atlanta, GA USA
[7] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Sch Med, Atlanta, GA USA
[8] Colorado Blood Canc Inst, Denver, CO USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-130644
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
602
引用
下载
收藏
页数：4
相关论文
共 50 条
  • [31] A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients
    Silvennoinen, Raija
    Waage, Anders
    Peceliunas, Valdas
    Schjesvold, Fredrik
    Anttila, Pekka
    Uttervall, Katarina
    Saily, Marjaana
    Putkonen, Mervi
    Carlson, Kristina
    Haukas, Einar
    Sankelo, Marja
    Partanen, Anu
    Szatkowski, Damian
    Hansson, Markus
    Marttila, Anu
    Svensson, Ronald
    Axelsson, Per
    Lauri, Birgitta
    Mikkola, Maija
    Karlsson, Conny
    Abelsson, Johanna
    Ahlstrand, Erik
    Sikio, Anu
    Nahi, Hareth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S157 - S157
  • [32] Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial
    Kumar, Shaji K.
    Lacy, Martha Q.
    Hayman, Suzanne R.
    Stewart, Keith
    Buadi, Francis K.
    Allred, Jacob
    Laumann, Kristina
    Greipp, Philip R.
    Lust, John A.
    Gertz, Morie A.
    Zeldenrust, Steven R.
    Bergsagel, P. Leif
    Reeder, Craig B.
    Witzig, Thomas E.
    Fonseca, Rafael
    Russell, Stephen J.
    Mikhael, Joseph R.
    Dingli, David
    Rajkumar, S. Vincent
    Dispenzieri, Angela
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (08) : 640 - 645
  • [33] Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyeLome (IFM) Krd Phase II Study
    Roussel, Murielle
    Lauwers-Cances, Valerie
    Robillard, Nelly
    Belhadj, Karim
    Facon, Thierry
    Garderet, Laurent
    Escoffre, Martine
    Pegourie, Brigitte
    Benboubker, Lotfi
    Caillot, Denis
    Fohrer, Cecile
    Moreau, Philippe
    Leleu, Xavier
    Avet-Loiseau, Herve
    Attal, Michel
    BLOOD, 2016, 128 (22)
  • [34] Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
    Gay, Francesca
    Musto, Pellegrino
    Rota-Scalabrini, Delia
    Bertamini, Luca
    Belotti, Angelo
    Galli, Monica
    Offidani, Massimo
    Zamagni, Elena
    Ledda, Antonio
    Grasso, Mariella
    Ballanti, Stelvio
    Spadano, Antonio
    Cea, Michele
    Patriarca, Francesca
    D'Agostino, Mattia
    Capra, Andrea
    Giuliani, Nicola
    de Fabritiis, Paolo
    Aquino, Sara
    Palmas, Angelo
    Gamberi, Barbara
    Zambello, Renato
    Petrucci, Maria Teresa
    Corradini, Paolo
    Cavo, Michele
    Boccadoro, Mario
    LANCET ONCOLOGY, 2021, 22 (12): : 1705 - 1720
  • [35] Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial
    Jakubowiak, Andrzej J.
    Dytfeld, Dominik
    Jagannath, Sundar
    Vesole, David H.
    Anderson, Tara B.
    Nordgren, Brian K.
    Lebovic, Daniel
    Stockerl-Goldstein, Keith E.
    Griffith, Kent A.
    Hill, Melissa A.
    Harvey, Colleen K.
    Dollard, Akari M.
    Ott, Robert
    Kelley, Susan L.
    Barrickman, Jennifer
    Kauffman, Michael
    Vij, Ravi
    BLOOD, 2010, 116 (21) : 376 - 377
  • [36] Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial
    Kubicki, Tadeusz
    Dytfeld, Dominik
    Wrobel, Tomasz
    Jamroziak, Krzysztof
    Robak, Pawel
    Czyz, Jaroslaw
    Tyczynska, Agata
    Druzd-Sitek, Agnieszka
    Giannopoulos, Krzysztof
    Szczepaniak, Tomasz
    Lojko-Dankowska, Anna
    Matuszak, Magdalena
    Gil, Lidia
    Pula, Bartosz
    Rybka, Justyna
    Majcherek, Maciej
    Usnarska-Zubkiewicz, Lidia
    Szukalski, Lukasz
    Zaucha, Jan Maciej
    Mikulski, Damian
    Czabak, Olga
    Lahoud, Oscar B.
    Stefka, Andrew
    Derman, Benjamin A.
    Jakubowiak, Andrzej J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (05) : 792 - 802
  • [37] Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.
    Richardson, Paul G.
    Jacobus, Susanna J.
    Weller, Edie
    Hassoun, Hani
    Lonial, Sagar
    Raje, Noopur S.
    Medvedova, Eva
    McCarthy, Philip L.
    Libby, Edward N.
    Voorhees, Peter M.
    Orlowski, Robert Z.
    Anderson, Larry D., Jr.
    Hurd, David D.
    Pasquini, Marcelo C.
    Masone, Kelly
    Moreau, Philippe
    Avet-Loiseau, Herve
    Attal, Michel
    Anderson, Kenneth Carl
    Munshi, Nikhil C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [38] Thalidomide and Dexamethasone Maintenance after Autologous Stem Cell Transplantation in Newly Diagnosed Korean Multiple Myeloma Patients: A Prospective Multi-Center Study in Asia
    Kim, Sang-A
    Yoon, Sung-Soo
    Koh, Youngil
    Shin, Dong-Yeop
    Kim, Jin Seok
    Kim, Kihyun
    Min, Chang-Ki
    Eom, Hyeon-Seok
    Lee, Je-Jung
    Lee, Jeong-Ok
    Bang, Soo-Mee
    BLOOD, 2017, 130
  • [39] MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab plus Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma
    Zamagni, Elena
    Boccadoro, Mario
    Spencer, Andrew
    Delforge, Michel
    Reece, Donna E.
    Szabo, Agoston Gyula
    Einsele, Hermann
    Terpos, Evangelos
    Schjesvold, Fredrik
    Bila, Jelena
    Driessen, Christoph
    Beksac, Meral
    Cook, Gordon
    Rodriguez, Cesar
    Pei, Lixia
    Shi, Yingqi
    Sakabedoyan, Caline
    Jasielec, Jagaoda
    Amin, Himal
    Kobos, Rachel
    Sonneveld, Pieter
    Van de Donk, Niels W. C. J.
    BLOOD, 2022, 140 : 7289 - 7291
  • [40] Results of a multi-center randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma following autologous stem cell transplant.
    Stewart, AK
    Chen, C
    Howson-Jan, K
    White, D
    Roy, J
    Kovacs, MJ
    Shustik, C
    Sadura, A
    Lois, S
    Ding, K
    Meyer, RM
    Belch, A
    BLOOD, 2004, 104 (11) : 99A - 99A
12345